1
|
Blass BE, Rogers JP. The sigma-2 (σ-2) receptor: a review of recent patent applications: 2013–2018. Expert Opin Ther Pat 2018; 28:655-663. [DOI: 10.1080/13543776.2018.1519024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Benjamin E. Blass
- Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, USA
| | - John Patrick Rogers
- Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, PA, USA
| |
Collapse
|
2
|
Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. Eur J Med Chem 2015; 106:15-25. [DOI: 10.1016/j.ejmech.2015.10.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 10/14/2015] [Accepted: 10/15/2015] [Indexed: 01/02/2023]
|
3
|
Oxombre B, Lee-Chang C, Duhamel A, Toussaint M, Giroux M, Donnier-Maréchal M, Carato P, Lefranc D, Zéphir H, Prin L, Melnyk P, Vermersch P. High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol 2015; 172:1769-82. [PMID: 25521311 PMCID: PMC4376455 DOI: 10.1111/bph.13037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Revised: 10/16/2014] [Accepted: 11/16/2014] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND AND PURPOSE Selective agonists of the sigma-1 receptor (σ1 protein) are generally reported to protect against neuronal damage and modulate oligodendrocyte differentiation. Human and rodent lymphocytes possess saturable, high-affinity binding sites for compounds binding to the σ1 protein and potential immunomodulatory properties have been described for σ1 protein ligands. Experimental autoimmune encephalomyelitis (EAE) is recognized as a valuable model of the inflammatory aspects of multiple sclerosis (MS). Here, we have assessed the role of a σ1 protein agonist, containing the tetrahydroisoquinoline-hydantoin structure, in EAE. EXPERIMENTAL APPROACH EAE was induced in SJL/J female mice by active immunization with myelin proteolipid protein (PLP)139-151 peptide. The σ1 protein agonist was injected i.p. at the time of immunization (day 0). Disease severity was assessed clinically and by histopathological evaluation of the CNS. Phenotyping of B-cell subsets and regulatory T-cells were performed by flow cytometry in spleen and cervical lymph nodes. KEY RESULTS Prophylactic treatment of EAE mice with the σ1 protein agonist prevented mononuclear cell accumulation and demyelination in brain and spinal cord and increased T2 B-cells and regulatory T-cells, resulting in an overall reduction in the clinical progression of EAE. CONCLUSIONS AND IMPLICATIONS This σ1 protein agonist, containing the tetrahydroisoquinoline-hydantoin structure, decreased the magnitude of inflammation in EAE. This effect was associated with increased proportions of B-cell subsets and regulatory T-cells with potential immunoregulatory functions. Targeting of the σ1 protein might thus provide new therapeutic opportunities in MS.
Collapse
MESH Headings
- Animals
- B-Lymphocytes/immunology
- Brain/drug effects
- Brain/pathology
- Cytokines/blood
- Encephalomyelitis, Autoimmune, Experimental/blood
- Encephalomyelitis, Autoimmune, Experimental/drug therapy
- Encephalomyelitis, Autoimmune, Experimental/immunology
- Encephalomyelitis, Autoimmune, Experimental/pathology
- Female
- Immunoglobulin G/blood
- Lymph Nodes/drug effects
- Lymph Nodes/immunology
- Mice
- Multiple Sclerosis/blood
- Multiple Sclerosis/drug therapy
- Multiple Sclerosis/immunology
- Multiple Sclerosis/pathology
- Myelin Proteolipid Protein/immunology
- Neuroprotective Agents/pharmacology
- Neuroprotective Agents/therapeutic use
- Peptide Fragments/immunology
- Receptors, sigma/agonists
- Spinal Cord/drug effects
- Spinal Cord/pathology
- Spleen/drug effects
- Spleen/immunology
- T-Lymphocytes, Regulatory/immunology
- Sigma-1 Receptor
Collapse
Affiliation(s)
- B Oxombre
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
| | - C Lee-Chang
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
| | - A Duhamel
- Université de LilleLille, France
- UDSL, EA 2694, UFR MédecineLille, France
| | - M Toussaint
- Université de LilleLille, France
- CNRS UMR8161Lille, France
| | - M Giroux
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
- Centre Hospitalier Régional et Universitaire de Lille, Pôle de neurologie–Service de Neurologie DLille, France
| | - M Donnier-Maréchal
- Université de LilleLille, France
- UDSL, EA 4481, UFR PharmacieLille, France
| | - P Carato
- Université de LilleLille, France
- UDSL, EA 4481, UFR PharmacieLille, France
| | - D Lefranc
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
| | - H Zéphir
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
- Centre Hospitalier Régional et Universitaire de Lille, Pôle de neurologie–Service de Neurologie DLille, France
| | - L Prin
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
- Centre Hospitalier Régional et Universitaire de Lille, Pôle d'immunologie–Centre de Biologie Pathologie et GénétiqueLille, France
| | - P Melnyk
- Université de LilleLille, France
- CNRS UMR8161Lille, France
- UDSL, EA 4481, UFR PharmacieLille, France
- Inserm UMR-S1172, Jean-Pierre Aubert Research CenterLille, France
| | - P Vermersch
- Université de LilleLille, France
- UDSL, EA2686-LIRIC, UFR MédecineLille, France
- UDSL, EA 4481, UFR PharmacieLille, France
| |
Collapse
|
4
|
Donnier-Maréchal M, Carato P, Le Broc D, Furman C, Melnyk P. Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands. Eur J Med Chem 2015; 92:575-82. [DOI: 10.1016/j.ejmech.2014.01.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2013] [Revised: 01/08/2014] [Accepted: 01/09/2014] [Indexed: 11/25/2022]
|
5
|
Donnier-Maréchal M, Larchanché PE, Le Broc D, Furman C, Carato P, Melnyk P. Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands. Eur J Med Chem 2015; 89:198-206. [PMID: 25462240 DOI: 10.1016/j.ejmech.2014.10.053] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Revised: 10/16/2014] [Accepted: 10/17/2014] [Indexed: 10/24/2022]
Abstract
Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders. These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents. The involvement of these receptors has also been observed in neuropathic pain and cancer. Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials. Thus the development of sigma 1 ligands is of interest to a new generation of drugs. Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands. Herein the work was extended to a series of novel tricyclic compounds. Carboline- and phenothiazine-derivated compounds were designed and synthesized. In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.
Collapse
Affiliation(s)
- Marion Donnier-Maréchal
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Paul-Emmanuel Larchanché
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Delphine Le Broc
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4483, UFR Pharmacie, F-59000 Lille, France.
| | - Christophe Furman
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4483, UFR Pharmacie, F-59000 Lille, France.
| | - Pascal Carato
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| | - Patricia Melnyk
- Univ Lille Nord de France, F-59000 Lille, France; UDSL, EA 4481, UFR Pharmacie, F-59000 Lille, France.
| |
Collapse
|
6
|
Xu Y, Brenning B, Clifford A, Vollmer D, Bearss J, Jones C, McCarthy V, Shi C, Wolfe B, Aavula B, Warner S, Bearss DJ, McCullar MV, Schuch R, Pelzek A, Bhaskaran SS, Stebbins CE, Goldberg AR, Fischetti VA, Vankayalapati H. Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents. ACS Med Chem Lett 2013; 4:1142-1147. [PMID: 24443700 DOI: 10.1021/ml4001936] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
We present the discovery and optimization of a novel series of inhibitors of bacterial UDP-N-acetylglucosamine 2-epimerase (called 2-epimerase in this paper). Starting from virtual screening hits, the activity of various inhibitory molecules was optimized using a combination of structure-based and rational design approaches. We successfully designed and identified a 2-epimerase inhibitor (compound 12-ES-Na, that we named Epimerox) which blocked the growth of methicillin-resistant Staphylococcus aureus (MRSA) at 3.9 μM MIC (minimum inhibitory concentration) and showed potent broad-range activity against all Gram-positive bacteria that were tested. Additionally a microplate coupled assay was performed to further confirm that the 2-epimerase inhibition of Epimerox was through a target-specific mechanism. Furthermore, Epimerox demonstrated in vivo efficacy and had a pharmacokinetic profile that is consonant with it being developed into a promising new antibiotic agent for treatment of infections caused by Gram-positive bacteria.
Collapse
Affiliation(s)
- Yong Xu
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Benjamin Brenning
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Adrianne Clifford
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - David Vollmer
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Jared Bearss
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Carissa Jones
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Virgil McCarthy
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Chongtie Shi
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Bradley Wolfe
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Bhasker Aavula
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Steve Warner
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - David J. Bearss
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Michael V. McCullar
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Raymond Schuch
- Laboratory
of Bacterial Pathogenesis and Immunology, The Rockefeller University, New
York, New York 10065, United States
| | - Adam Pelzek
- Laboratory
of Bacterial Pathogenesis and Immunology, The Rockefeller University, New
York, New York 10065, United States
| | - Shyam S. Bhaskaran
- Laboratory
of Bacterial Pathogenesis and Immunology, The Rockefeller University, New
York, New York 10065, United States
| | - C. Erec Stebbins
- Laboratory of Structural Microbiology, The Rockefeller University, New York, New York 10065, United States
| | - Allan R. Goldberg
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| | - Vincent A. Fischetti
- Laboratory
of Bacterial Pathogenesis and Immunology, The Rockefeller University, New
York, New York 10065, United States
| | - Hariprasad Vankayalapati
- Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), 4140 Dublin Boulevard, Suite 200, Dublin, California 94568, United States
| |
Collapse
|
7
|
Sadeghzadeh M, Sheibani S, Ghandi M, Daha FJ, Amanlou M, Arjmand M, Hasani Bozcheloie A. Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands. Eur J Med Chem 2013; 64:488-97. [DOI: 10.1016/j.ejmech.2013.04.013] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 04/02/2013] [Accepted: 04/03/2013] [Indexed: 11/30/2022]
|
8
|
Cheng L, Liu L, Li C, Jia H, Wang D, Chen YJ. Nucleophilic addition of regioselectively lithiated indoline with aldimines for the syntheses of 2- and 7-indolinyl methanamine derivatives. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.05.119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
9
|
Cabordery AC, Toussaint M, Bonte JP, Melnyk P, Vaccher C, Foulon C. Separation of Tic-hydantoin enantiomers, potent sigma-1 agonists, by high performance liquid chromatography and capillary electrophoresis. J Chromatogr A 2010; 1217:3871-5. [PMID: 20451916 DOI: 10.1016/j.chroma.2010.04.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2009] [Revised: 03/26/2010] [Accepted: 04/08/2010] [Indexed: 11/21/2022]
Abstract
Stereospecific separations of seven Tic-hydantoin sigma-1 agonists were performed by both HPLC method using derivatized cellulose and amylose chiral stationary phases and capillary electrophoresis (CE) method using neutral and anionic cyclodextrins added in the background electrolyte (BGE). An optimal baseline separation (R(s)>3.3 with analysis times<25min) was readily obtained with all silica-based celluloses and amyloses using a normal-phase methodology. CE was used as an alternative technique to HPLC for the Tic-hydantoin derivatives separation. The enantiomers were fully resolved with highly sulfated beta-cyclodextrins at pH 2.5 (R(s)>1.5 with analysis times <11min). Both methods were validated in terms of linearity, detection and quantification limits. They were used to check the enantiomeric purity of the enantiomers.
Collapse
Affiliation(s)
- A C Cabordery
- UDSL, UFR Pharmacie,Laboratoire de Chimie Analytique, EA 4034, F-59000 Lille, France
| | | | | | | | | | | |
Collapse
|
10
|
Blanco-Ania D, Valderas-Cortina C, Hermkens PH, Sliedregt LA, Scheeren HW, Rutjes FP. Synthesis of dihydrouracils spiro-fused to pyrrolidines: druglike molecules based on the 2-arylethyl amine scaffold. Molecules 2010; 15:2269-301. [PMID: 20428042 PMCID: PMC6257290 DOI: 10.3390/molecules15042269] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Revised: 03/26/2010] [Accepted: 03/30/2010] [Indexed: 11/16/2022] Open
Abstract
The synthesis of a small library of dihydrouracils spiro-fused to pyrrolidines is described. These compounds are synthesized from beta-aryl pyrrolidines, providing products with the 2-arylethyl amine moiety, a structural feature often encountered in compounds active in the central nervous system. The b-aryl pyrrolidines are synthesized through a three-step methodology that includes a Knoevenagel condensation reaction, a 1,3-dipolar cycloaddition reaction, and a nitrile reduction.
Collapse
Affiliation(s)
- Daniel Blanco-Ania
- Institute for Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Carolina Valderas-Cortina
- Institute for Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | | | - Leo A.J.M. Sliedregt
- Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| | - Hans W. Scheeren
- Institute for Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| | - Floris P.J.T. Rutjes
- Institute for Molecules and Materials, Radboud University Nijmegen, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands
| |
Collapse
|
11
|
Toussaint M, Mousset D, Foulon C, Jacquemard U, Vaccher C, Melnyk P. Sigma-1 ligands: Tic-hydantoin as a key pharmacophore. Eur J Med Chem 2010; 45:256-63. [PMID: 19875205 DOI: 10.1016/j.ejmech.2009.10.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2009] [Revised: 08/10/2009] [Accepted: 10/01/2009] [Indexed: 10/20/2022]
Abstract
Sigma-1 receptors are involved in numerous pathological dysfunctions and the synthesis of selective ligands is of interest. We identified a fused tetrahydroisoquinoline-hydantoin (Tic-hydantoin) structure with high affinity and selectivity for these receptors. We report here our efforts towards the pharmacomodulation of this substructure, the synthesis of 9 analogs with stereochemistry inversion, opening of isoquinoline ring, removal of isoquinoline nitrogen, replacement of isoquinoline by pyridine, of Tic-hydantoin moiety by quinazolinedione heterocycle. All these analogs provided a loss in the affinity for the sigma-1 receptor. The present work underlines the real importance of the Tic-hydantoin moiety for the obtainment of high affinity ligands.
Collapse
Affiliation(s)
- Marion Toussaint
- UMR CNRS 8161-Université Lille Nord de France-Institut Pasteur de Lille, 1 rue du Professeur Calmette, B.P. 447, 59021 Lille cedex, France
| | | | | | | | | | | |
Collapse
|
12
|
Toussaint M, Delair B, Foulon C, Lempereur N, Vaccher C, Maurice T, Melnyk P. Tic hydantoin sigma-1 agonist: pharmacological characterization on cocaine-induced stimulant and appetitive effects. Eur Neuropsychopharmacol 2009; 19:504-15. [PMID: 19249191 DOI: 10.1016/j.euroneuro.2009.01.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2008] [Revised: 01/13/2009] [Accepted: 01/27/2009] [Indexed: 10/21/2022]
Abstract
Activation of the newly identified sigma(1) chaperone protein is involved in several aspects of the psychostimulant and addictive effects of cocaine. The development of ligands that selectively target the sigma(1) protein may lead to putative potent anti-cocaine agents. Here, we synthetized substituted hydantoins with high affinity for the sigma(1) protein and evaluated their behavioral efficacy. Two pure enantiomers were designed and synthesized: tetrahydroisoquinoleine-hydantoin fused compounds 3 and 4. They increased cocaine-induced locomotor stimulation or sensitization. The most active enantiomer 4, facilitated CPP acquisition but failed to substitute for cocaine. When CPP was acquired with cocaine and then extinguished, 4 provoked reactivation of CPP. These observations showed that compound 4 shows a typical profile of sigma(1) protein activator, facilitating cocaine-induced behavioral effects. Preliminary ADME properties are in favour of an optimal therapeutic development. Such Tic-hydantoin compound may serve as a new effective agonist therapy in cocaine addiction.
Collapse
Affiliation(s)
- Marion Toussaint
- CNRS UMR 8161, Team 3, Lille 2 University, Lille 1 University, Pasteur Institute of Lille, 59021 Lille, France
| | | | | | | | | | | | | |
Collapse
|
13
|
Blanco-Ania D, Hermkens PHH, Sliedregt LAJM, Scheeren HW, Rutjes FPJT. Solution-Phase Parallel Annulation of (Thio)hydantoins to Tetrahydroisoquinolines and Tetrahydro-β-carbolines Containing the 2-Arylethyl Amine Scaffold. ACTA ACUST UNITED AC 2009; 11:547-55. [DOI: 10.1021/cc8001926] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Daniel Blanco-Ania
- Institute for Molecules and Materials, Radboud University Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands, Schering-Plough, P.O. Box 20, 5340 BH Oss, The Netherlands; and Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| | - Pedro H. H. Hermkens
- Institute for Molecules and Materials, Radboud University Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands, Schering-Plough, P.O. Box 20, 5340 BH Oss, The Netherlands; and Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| | - Leo A. J. M. Sliedregt
- Institute for Molecules and Materials, Radboud University Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands, Schering-Plough, P.O. Box 20, 5340 BH Oss, The Netherlands; and Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| | - Hans W. Scheeren
- Institute for Molecules and Materials, Radboud University Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands, Schering-Plough, P.O. Box 20, 5340 BH Oss, The Netherlands; and Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| | - Floris P. J. T. Rutjes
- Institute for Molecules and Materials, Radboud University Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands, Schering-Plough, P.O. Box 20, 5340 BH Oss, The Netherlands; and Solvay Pharmaceuticals, Sector Discovery Weesp, P.O. Box 900, 1380 DA Weesp, The Netherlands
| |
Collapse
|
14
|
Antipin RL, Beloglazkina EK, Magouga AG, Chernysheva AN, Zyk NV. A new method for the synthesis of 5-bromo(aryl)methylene-substituted hydantoins. Chem Heterocycl Compd (N Y) 2008. [DOI: 10.1007/s10593-008-0167-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Hok S, Natarajan A, Balhorn R, DeNardo SJ, DeNardo GL, Perkins J. Synthesis and Radiolabeling of Selective High-Affinity Ligands Designed to Target Non-Hodgkin's Lymphoma and Leukemia. Bioconjug Chem 2007; 18:912-21. [PMID: 17373772 DOI: 10.1021/bc060305o] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Selective high-affinity ligands (SHALs) were synthesized as molecular targeting agents for HLA-DR10, a cell surface receptor upregulated on malignant B-cell lymphocytes in non-Hodgkin's lymphoma and leukemia. SHALs are designed to mimic the affinity and selectivity of Lym-1, an antibody that binds to the beta-subunit of HLA-DR10. To bind selectively to HLA-DR10, SHALs were constructed to bind to two adjacent pockets on the surface of the beta-subunit of HLA-DR10 located within an epitope recognized by the Lym-1 antibody. A series of multivalent SHALs with molecular masses of 1500-3000 Da were synthesized using solid/polymer-supported synthesis on chlorotrityl chloride resin in 50-80% yield. To enable their use as radionuclide carriers in mouse studies, SHALs were conjugated to DOTA in a solution-phase reaction with 70-100% yield. 57Co/CoCl2 titrations revealed that 50-60% of the DOTA in the DOTA-conjugated SHALs was available for radiometal chelation. These DOTA-SHALs were labeled with 111In and used to carry out pharmacokinetic studies in mice. Radiolabeling reactions of DOTA-SHALs, with exactly one DOTA entity per targeting SHAL molecule, yielded products with greater than 90% radiochemical purity and specific activities ranging from 97 to 150 muCi/mug.
Collapse
Affiliation(s)
- Saphon Hok
- Chemistry, Materials and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, California 94551, USA
| | | | | | | | | | | |
Collapse
|